DCIS and aromatase inhibitors

Journal of Steroid Biochemistry and Molecular Biology

Volumn 106, Issue 1-5, 2007, Pages 173-179

  Dixon, J Michael ^a   Faratian, Dana ^a   White, Sharon ^a   Renshaw, Lorna ^a   Murray, Juliette ^a   Young, Oliver ^a   Macaskill, E Jane ^a   Williams, Linda ^b   Thomas, Jeremy ^a   Evans, Dean B ^c  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Aromatase inhibitors; DCIS

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; HORMONE RECEPTOR; KI 67 ANTIGEN; LETROZOLE; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN;

ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CARCINOMA IN SITU; CELL PROLIFERATION; CLINICAL TRIAL; HUMAN; PROTEIN EXPRESSION;

ADJUVANTS, PHARMACEUTIC; AROMATASE INHIBITORS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL PROLIFERATION; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NITRILES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 34548406490     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.05.015     Document Type: Article

References (21)

1. Page D.L., Bundred N.J., and Steel C.M. Carcinoma in situ and patients at high risk of breast cancer. In: Dixon J.M. (Ed). ABC of Breast Diseases. third ed. (2006), Blackwell Publishing Ltd., Oxford 92-99
2. Fisher B., Dignam J., Wolmark N., Wickerham D.L., Fisher E.R., Mamounas E., Smith R., Begovic M., Dimitrov N.V., Margolese R.G., Kardinal G.C., Kavanah M.T., Fehrenbacher L., and Oishi R.H. Tamoxifen in the treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353 (1999) 1993-2000
3. Houghton J., George W.D., Cuzick J., Duggan C., Fentiman I.S., and Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia and New Zealand randomised controlled trial. Lancet 362 (2003) 95-102
4. Allred D.C., Bryant J., Land S., Paik S., Fisher E., Julian T., Margolese R., Smith R., Mamounas T., Osborne C.K., Fisher B., and Wolmark N. Estrogen receptor expression as a predictive marker of effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP B-24. Br. Ca. Res. Treat. 76 (2002) S36
5. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (1998) 1451-1467
6. Fisher B., et al. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel project P-1 Study. J. Natl. Ca. Inst. 90 (1998) 1371-1387
7. Fisher B., Land S., Mamoumas E., Dignam J., Fisher E.R., and Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin. Oncol. 28 (2001) 400-418
8. Cuzick J., et al. First results from the International Breast Cancer Intervention Study (IBIS 1): a randomised prevention trial. Lancet 360 (2002) 817-824
9. Smith I.E., and Chua S. Medical treatment of early breast cancer. II: endocrine therapy. BMJ 332 (2006) 101-103
10. Howell A. The ATAC ('Arimidex', Tamoxifen, alone or in combination) trial in postmenopausal women with early breast cancer: updated efficacy results based on a median follow-up of 5 years. Br. Ca. Res. Treat. 88 Suppl. 1 (2004) S7
11. Thurlimann B., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353 (2005) 2747-2757
12. Jonat W., Gnant M., Boccardo F., Kaufmann M., Rubagotti A., and Jakesz R. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: a meta-analysis of the ARNO 95 trial, ABCSG trial 8, and the ITA trial. Br. Ca. Res. Treat. 94 Suppl. 1 (2005) S11
13. Coombes R.C., Hall E., Gibson L.J., Mouridsen H., Mauriac L., Forbes J.F., Paridaens R., Castiglione-Gertsch M., Gelber M.R.D., Rabaglio M., Smith I., Wardley A., Price K.N., and Goldhirsch A. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350 (2004) 1081-1092
14. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., Castiglione M., Tu D., Shepherd L.E., Pritchard K.I., Livingston R.B., Davidson N.E., Norton L., Perez E.A., Abrams J.S., Therasse P., Palmer M.J., and Pater J.L. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349 (2003) 1793-1802
15. Murray J., Young O., Renshaw L., White S., Prescot R.J., Evans D.B., Salem R., Cameron D., Dowsett M., Anderson T.J., Miller W.R., and Dixon J.M. Letrozole versus anastrozole: a pre-operative comparative study of their effects on ER positive breast cancers in postmenopausal women. Breast Cancer Res. Treat. (2005)
16. Smith I.E., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol. 23 (2005) 5108-5116
17. Dowsett M., Smith I.E., Ebbs S.R., Dixon J.M., Skene A., Griffith C., Boeddinghaus I., Salter J., Detre S., Hills M., Ashley S., Francis S., Walsh G., and Trialists IMPACT. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin. Cancer Res. 11 (2005) 951s-958s
18. Robertson J.F., Nicholson R.I., Bundred N.J., Anderson E., Rayter Z., Dowsett M., Fox J.N., Gee J.M., Webster A., Wakeling A.E., Morris C., and Dixon M. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res. 61 18 (2001) 6739-6746
19. Werner M., Chott A., Fabiano A., and Battifora H. Effect of formalin tissue fixation and processing on immunohistochemistry. Am. J. Surg. Pathol. 24 7 (2000) 1016-1019
20. Miller W.R., Anderson T.J., White S., Larionov A., Murray J., Evans D., Krause A., and Dixon J.M. Aromatase inhibitors: cellular and molecular effects. J. Steroid Biochem. Mol. Biol. 95 (2005) 83-89
21. Ellis J., Tao Y., Young O., White S., Proia A.D., Murray J., Renshaw L., Faratian D., Thomas J., Dowsett M., Krause A., Evans D.B., Miller W.R., and Dixon J.M. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J. Clin. Oncol. 24 19 (2006) 3019-3025